Drugs / Pumecitinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06837233 | Mar → May 2025 overdue | seasonal allergic rhinitis | Prime Gene Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07146126 | Sep 2025 → Jun 2026 overdue | seasonal allergic rhinitis | Prime Gene Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06587685 | Mar → Nov 2024 overdue | atopic eczema | Prime Gene Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pumecitinib | “Topically administered Pumecitinib Gel 3% to the skin twice daily for 52 or 44 weeks” NCT06587685 ↗ |
| Known as | PG-011 | “PG-011 nasal spray 0.6% (1.2mg Pumecitinib) administered twice daily.” NCT07146126 ↗1“PG-011 nasal spray 0.3% ( 0.6mg Pumecitinib)” NCT06837233 ↗ |
| Modality | Small molecule | — CHEMBL5314478 ↗ |
| Route | Topical | “Topically administered Pumecitinib Gel 3% to the skin twice daily for 52 or 44 weeks” NCT06587685 ↗ |